These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates]. Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226 [TBL] [Abstract][Full Text] [Related]
31. Meropenem-Vaborbactam Activity against Carbapenem-Resistant Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207 [TBL] [Abstract][Full Text] [Related]
32. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821 [TBL] [Abstract][Full Text] [Related]
33. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin. Sato T; Yamawaki K Clin Infect Dis; 2019 Nov; 69(Suppl 7):S538-S543. PubMed ID: 31724047 [TBL] [Abstract][Full Text] [Related]
34. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance. Kayama S; Kawakami S; Kondo K; Kitamura N; Yu L; Hayashi W; Yahara K; Sugawara Y; Sugai M J Glob Antimicrob Resist; 2024 May; 38():12-20. PubMed ID: 38789082 [TBL] [Abstract][Full Text] [Related]
35. In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales. Ozyurt OK; Tufanoglu P; Cetinkaya O; Ozhak B; Yazisiz H; Ongut G; Turhan O; Ogunc D Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649528 [TBL] [Abstract][Full Text] [Related]
36. Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. Lasko MJ; Nicolau DP Curr Infect Dis Rep; 2020 Feb; 22(3):6. PubMed ID: 32034524 [TBL] [Abstract][Full Text] [Related]
37. Nelson K; Rubio-Aparicio D; Sun D; Dudley M; Lomovskaya O Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482673 [TBL] [Abstract][Full Text] [Related]
38. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Wright H; Bonomo RA; Paterson DL Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690 [TBL] [Abstract][Full Text] [Related]
39. Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F; Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963 [TBL] [Abstract][Full Text] [Related]
40. Role of new antibiotics for KPC-producing Klebsiella pneumoniae. Theuretzbacher U; Carrara E; Conti M; Tacconelli E J Antimicrob Chemother; 2021 Jan; 76(Suppl 1):i47-i54. PubMed ID: 33534882 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]